Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod With Fish Oil in Relapsing-Remitting Multiple Sclerosis
NCT02939079Phase 3Completed
- Start
- Apr 2015
- Primary completion
- Sep 2016
01
Overview
Phase 3, randomised trial in multiple sclerosis (MS) (2 arms). Primary endpoints: Serum Level of Tumor Necrosis Factor-α at 1 year, Serum Level of Interleukin-1b at 1 year and 2 more. Started Apr 2015; status: completed.
02
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02939079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02939079.